Luo Ning, Lin Yi, Feng Jing, Cai Linbo, Zhang Yongli, Wang Xingfu, Mei Wenzhong, Li Hao, Liu Bei, Qi Xueling, Lin Zhixiong
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Beijng, 100093, China.
Sci Rep. 2025 Jul 28;15(1):27422. doi: 10.1038/s41598-025-12662-8.
Papillary craniopharyngioma (PCP) was previously believed to occur only in adults. Sporadic pediatric PCP (PPCP), confirmed by detection of the BRAF V600E mutation, has been reported since 2018. The differences between PPCP and adult PCP (APCP) remain unclear. This comprehensive study aimed to enhance understanding of PPCP and elucidate the distinctions between PPCP and APCP. We conducted a systematic analysis of cases of PPCP and APCP, focusing on BRAF V600E mutation, methylation profiles, histology, cell proliferation, imaging features, immune microenvironment, and prognosis. This study compiled 17 cases of PPCP from 6 medical centers, constituting 3.11% of the total 546 PCP cases. Both PPCP and APCP cases exhibited the BRAF V600E mutation with no differences in methylation patterns. However, imaging showed PPCP was predominantly cystic and located beneath the diaphragma sellae with some progression to the sella. APCP typically manifested as solid lesions, primarily located in the suprasellar region, inferior to the third ventricle. PPCP histologically displayed extensive inflammatory cellular infiltration, suppurative change, and occasional small granular calcifications, whereas APCP was largely devoid of calcifications. Compared to APCP, PPCP exhibited significantly lower PD-L1 (an immune checkpoint protein expressed on tumor cells) expression and higher expression levels of CD38 (an immunosuppressive marker), S100A8/A9 (a neutrophil marker), and MPO (myeloperoxidase, a neutrophil marker). Additionally, stromal expression of CD163 (an M2 macrophage marker) was lower in PPCP compared to APCP, while CD68 (an M1 macrophage marker), CD3 (T cell marker), and CD20 (B cell marker) expression showed no significant difference. Ki-67 expression exhibited a banded pattern on PPCP epithelium, contrasting with a punctate pattern in APCP, with significantly higher levels observed in PPCP. Postoperative prognosis did not differ between PPCP and APCP. While driver genes and methylation profiles may not differentiate PPCP from APCP, substantial discrepancies exist in tumor location, histology, imaging features, cell proliferation, and immune microenvironment.
乳头型颅咽管瘤(PCP)以前被认为仅发生于成人。自2018年以来,已有通过检测BRAF V600E突变确诊的散发性儿童PCP(PPCP)的报道。PPCP与成人PCP(APCP)之间的差异仍不清楚。这项全面的研究旨在加深对PPCP的理解,并阐明PPCP与APCP之间的区别。我们对PPCP和APCP病例进行了系统分析,重点关注BRAF V600E突变、甲基化谱、组织学、细胞增殖、影像学特征、免疫微环境和预后。本研究收集了来自6个医疗中心的17例PPCP病例,占546例PCP病例总数的3.11%。PPCP和APCP病例均表现出BRAF V600E突变,甲基化模式无差异。然而,影像学显示PPCP主要为囊性,位于鞍隔下方,部分向鞍内进展。APCP通常表现为实性病变,主要位于鞍上区域,第三脑室下方。PPCP在组织学上表现为广泛的炎性细胞浸润、化脓性改变和偶尔的小颗粒状钙化,而APCP大多无钙化。与APCP相比,PPCP表现出显著更低的PD-L1(一种在肿瘤细胞上表达的免疫检查点蛋白)表达以及更高的CD38(一种免疫抑制标志物)、S100A8/A9(一种中性粒细胞标志物)和MPO(髓过氧化物酶,一种中性粒细胞标志物)表达水平。此外,与APCP相比,PPCP中CD163(一种M2巨噬细胞标志物)的基质表达更低,而CD68(一种M1巨噬细胞标志物)、CD3(T细胞标志物)和CD20(B细胞标志物)的表达无显著差异。Ki-67表达在PPCP上皮上呈带状模式,与APCP中的点状模式形成对比,在PPCP中观察到的水平显著更高。PPCP和APCP术后预后无差异。虽然驱动基因和甲基化谱可能无法区分PPCP和APCP,但在肿瘤位置、组织学、影像学特征、细胞增殖和免疫微环境方面存在显著差异。